Addus HomeCare Corporation (ADUS) experienced a significant downturn in Tuesday's trading session, with its stock plummeting 5.57% despite receiving a target price increase from Barclays. The conflicting signals from the investment bank appear to have unsettled investors, triggering a substantial sell-off.

Barclays raised its target price for Addus HomeCare from $111 to $117, which would typically be viewed as a positive development. However, the investment bank simultaneously maintained its Underweight rating on the stock. This preservation of a bearish outlook seems to have overshadowed the increased price target in the eyes of investors.

The market's strong negative reaction suggests that investors are placing more emphasis on the maintained Underweight rating than on the higher target price. This could indicate persistent concerns about Addus HomeCare's fundamental performance or its competitive position within the home healthcare sector. As the trading session progressed, the selling pressure intensified, resulting in the substantial 5.57% drop by the close of the market.